Developing potent human uric acid transporter 1 (hURAT1) inhibitors

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 2701-2713

  Wempe, Michael F ^a,b   Jutabha, Promsuk ^c   Quade, Bettina ^a   Iwen, Timothy J ^a   Frick, Morin M ^a   Ross, Ian R ^b   Rice, Peter J ^a,b   Anzai, Naohiko ^c   Endou, Hitoshi ^c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d J Pharma Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFURAN DERIVATIVE; CARBON 14; HUMAN URIC ACID TRANSPORTER 1; HUMAN URIC ACID TRANSPORTER 1 INHIBITOR; ORGANIC ANION TRANSPORTER; PHENOL DERIVATIVE; UNCLASSIFIED DRUG; URIC ACID; URICOSURIC AGENT;

ACID BASE BALANCE; ARTICLE; BROMINATION; DRUG POTENCY; ELECTROLYTE BALANCE; EXTRACELLULAR FLUID; IC 50; IN VITRO STUDY; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MOLECULAR PROBE; NONHUMAN; OOCYTE; STRUCTURE ACTIVITY RELATION; XENOPUS;

ANIMALS; DRUG DESIGN; HUMANS; KIDNEY; MAGNETIC RESONANCE SPECTROSCOPY; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; XENOPUS;

EID: 79955407045     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1015022     Document Type: Article

References (29)

1. Neogi, T. Clinical Practice. Gout N. Engl. J. Med. 2011, 364, 443-452
2. Zubay, G. L. Biochemistry, 4 th ed.; Wm. C. Brown Publishers: Dubuque, IA, 1998; Chapter 26, pp 629 - 665.
3. Shin, H. J.; Takeda, M.; Enomoto, A.; Fujimura, M.; Miyazaki, H.; Anazi, N.; Endou, H. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs Nephrology 2011, 16, 156-162
4. Saag, K. G.; Choi, H. Epidemiology, risk factors, and lifestyle modifications for gout Arthritis Res. Ther. 2006, 8 (Suppl. 1) S2
5. Anzai, N.; Jutabha, P.; Endou, H. Renal Solute Transporters and Their Relevance to Serum Urate Disorder Curr. Hypertens. Rev. 2010, 6, 148-154
6. Lemke, T. L.; Williams, D. A. Foye's Principles of Medicinal Chemistry, 6 th ed.; Lippincott Williams & Wilkins: Philadelphia, 2008; pp 998 - 1001.
7. Biggers, K.; Scheinfeld, N. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout Curr. Opin. Invest. Drugs 2008, 9, 422-429 (Pubitemid 351507668)
8. Becker, M. A.; Jolly, M. Hyperuricemia and associated diseases Rheum. Dis. Clin. North Am. 2006, 32, 275-293 (Pubitemid 43728824)
9. Anzai, N.; Kanai, Y.; Endou, H. New insights into renal transport of urate Curr. Opin. Rheumatol. 2007, 19, 151-157 (Pubitemid 46208773)
10. Kutzing, M. K.; Firestein, B. L. Altered uric acid levels and disease states J. Pharmacol. Exp. Ther. 2008, 324, 1-7 (Pubitemid 350294141)
11. Enomoto, A.; Kimura, H.; Chairoungdua, A.; Shigeta, Y.; Jutabha, P.; Cha, S. H.; Hosoyamada, M.; Takeda, M.; Sekine, T.; Igarashi, T.; Matsuo, H.; Kikuchi, Y.; Oda, T.; Ichida, K.; Hosoya, T.; Shimokata, K.; Niwa, T.; Kanai, Y.; Endou, H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels Nature 2002, 417, 447-452 (Pubitemid 34563537)
12. Roch-Ramel, F.; Guisan, B. Renal Transport of Urate in Humans News Physiol. Sci. 1999, 14, 80-84
13. Mount, D. B.; Kwon, C. Y.; Zandi-Nejad, K. Renal urate transport Rheum. Dis. Clin. North Am. 2006, 32, 313-331 (Pubitemid 43728821)
14. Jutabha, P.; Anzai, N.; Kitamura, K.; Taniguchi, A.; Kaneko, S.; Yan, K.; Yamada, H.; Shimada, H.; Kimura, T.; Katada, T.; Fukutomi, T.; Tomita, K.; Urano, W.; Yamanaka, H.; Seki, G.; Fujita, T.; Moriyama, Y.; Yamada, A.; Uchida, S.; Wempe, M. F.; Endou, H.; Sakurai, H. Human sodium-phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate J. Biol. Chem. 2010, 285, 35123-35132
15. Anzai, N.; Ichida, K.; Jutabha, P.; Kimura, T.; Babu, E.; Jin, C. J.; Srivastava, S.; Kitamura, K.; Hisatome, I.; Endou, H.; Sakurai, H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans J. Biol. Chem. 2008, 283, 26834-26838
16. Caulfield, M. J.; Munroe, P. B.; O'Neill, D.; Witkowska, K.; Charchar, F. J.; Doblado, M.; Evans, S.; Eyheramendy, S.; Onipinla, A.; Howard, P.; Shaw-Hawkins, S.; Dobson, R. J.; Wallace, C.; Newhouse, S. J.; Brown, M.; Connell, J. M.; Dominiczak, A.; Farrall, M.; Lathrop, G. M.; Samani, N. J.; Kumari, M.; Marmot, M.; Brunner, E.; Chambers, J.; Elliott, P.; Kooner, J.; Laan, M.; Org, E.; Veldre, G.; Viigimaa, M.; Cappuccio, F. P.; Ji, C.; Lacone, R.; Strazzullo, P.; Moley, K. H.; Cheeseman, C. SLC2A9 is a high-capacity urate transporter in humans PLoS Med. 2008, 5, e197
17. Vitart, V.; Rudan, I.; Hayward, C.; Gray, N. K.; Floyd, J.; Palmer, C. N.; Knott, S. A.; Kolcic, I.; Polasek, O.; Graessler, J.; Wilson, J. F.; Marinaki, A.; Riches, P. L.; Shu, X.; Janicijevic, B.; Smolej-Narancic, N.; Gorgoni, B.; Morgan, J.; Campbell, S.; Biloglav, Z.; Barac-Lauc, L.; Pericic, M.; Klaric, I. M.; Zgaga, L.; Skaric-Juric, T.; Wild, S. H.; Richardson, W. A.; Hohenstein, P.; Kimber, C. H.; Tenesa, A.; Donnelly, L. A.; Fairbanks, L. D.; Aringer, M.; McKeigue, P. M.; Ralston, S. H.; Morris, A. D.; Rudan, P.; Hastie, N. D.; Campbell, H.; Wright, A. F. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout Nat. Genet. 2008, 40, 437-442 (Pubitemid 351450879)
18. Sekine, T.; Watanabe, N.; Hosoyamada, M.; Kanai, Y.; Endou, H. Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter J. Biol. Chem. 1997, 272, 18526-18529 (Pubitemid 27318187)
19. Arias, E.; Anderson, R. N.; Kung, H.-C.; Murphy, S. L.; Kochanek, K. D. Division of Vital Statistics. Deaths: Final Data for 2001 Natl. Vital Stat. Rep. 2003, 52, 1-116
20. Feig, D. I.; Kang, D. H.; Johnson, R. J. Uric acid and cardiovascular risk N. Engl. J. Med. 2008, 359, 1811-1821
21. McDonald, M. G.; Rettie, A. E. Sequential Metabolism and Bioactivation of the Hepatotoxin Benzbromarone: Formation of Glutathione Adducts from a Catechol Intermediate Chem. Res. Toxicol. 2007, 20, 1833-1842
22. Lee, M. H.; Graham, G. G.; Williams, K. M.; Day, R. O. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008, 31, 643-665 (Pubitemid 352019563)
23. Kürti, L.; Czakó, B. Strategic applications of named reactions in organic synthesis. Elsevier Academic Press: Burlington, MA, 2005; pp 484 and 496.
24. Smith, M. B.; March, J. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6 th ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2007; Chapter 11, pp 657 - 751.
25. Wuts, P. G. M.; Greene, T. W. Greene's Protective Groups in Organic Synthesis, 4 th ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2007; Chapter 3, pp 367 - 430.
26. Pombrio, J. M.; Giangreco, A.; Li, L.; Wempe, M. F.; Anders, M. W.; Sweet, D. H.; Pritchard, J. B.; Ballatori, N. Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1 Mol. Pharmacol. 2001, 60, 1091-1099 (Pubitemid 33027445)
27. 3H]digoxin efflux Pharmacol. Res. 2010, 61, 76-84
28. Ohtsu, N.; Otomo, J.; Anzai, N.; Sakata, T.; Jutabha, P.; Narikawa, S.; Kadota, T.; Endou, H. Development of the alternative method for renal drug excretion using Xenopus oocyte expression system combined with a high throughput method. OOCYTEXPRESS, AATEX 2007; Vol. 14, pp SI 669 - SI671.
29. Endou, H.; Olkawa, T. Medicinal Compositions Containing 6-Hydroxybenzbromarone or Salts Thereof. U.S. Patent US 7,521-570 B2, 2009.